Enliven Therapeutics Inc (ELVN)

$22.07 +1.80 (8.88%)
Market Cap 1.31B
Revenue (ttm) 0.00
Net Income (ttm) -89.02M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 565,700
Avg Vol 567,986
Day's Range N/A - N/A
Shares Out 59.35M
Stochastic %K 95%
Beta 0.80
Analysts Strong Sell
Price Target $41.38

Company Profile

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a CNS penetrant and irreversible HER2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and...

Industry: Biotechnology
Sector: Healthcare
Phone: 720 647 8519
Address:
6200 Lookout Road, Boulder, United States
d_risk
d_risk Nov. 12 at 10:23 PM
$ELVN - Enliven Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors ELVN flags new risks from costly companion diagnostic regulations, urgent need for substantial funding, dependence on key personnel and third parties, cybersecurity threats, and disaster impacts, while expanding on volatility, dilution, regulatory, and commercialization challenges. #Biotechnology #MarketVolatility #CybersecurityThreats #FundingChallenges #RegulatoryRisk 🟢 Added 🟠 Removed https://d-risk.ai/ELVN/10-Q/2025-11-12
0 · Reply
notreload_ai
notreload_ai Nov. 3 at 8:30 PM
Mizuho says $TERN TERN-701 data looks fine, but the market is overreacting by pushing $ELVN stock down 19%. The two treat different patients [ELVN-001], so the drop “makes no sense.” Mizuho expects Enliven to rebound on strong fundamentals; keeps $41 target and Outperform.
0 · Reply
Quantumup
Quantumup Nov. 3 at 7:36 PM
Oppenheimer⬆️ $TERN's PT to $24 from $17 and reiterated at an Outperform rating. $NVS Oppenheimer said, TERN shares are rallying (+88% vs. -3% $XBI and -20% $ELVN) following a newly-released ASH abstract detailing promising preliminary Ph1 CARDINAL data with June 2025 data cutoff, specifically: 1) impressive cumulative 6-mo. MMR rate of 75% (n=24/32), which appears potentially superior against asciminib [NVS] and ELVN-001; 2) 64% of evaluable patients (n=14/22) not in MMR at baseline achieved MMR, also notable compared to the 6-mo. MMR achievement for asciminib/ELVN-001; 3) 6-mo. overall MMR in asciminib-experienced patients of 60% versus 32% in ELVN-001's Ph1 ENABLE trial; and 4) on safety, no dose-limiting toxicities or pancreatic/cardiovascular safety signals, with only one patient discontinuing the study due to adverse events. We see these initial results bolstering '701's competitive positioning and accordingly raise our PT to $24 (vs. $17 prior).
0 · Reply
kshonstocks
kshonstocks Sep. 29 at 2:29 PM
$ELVN positive Barrons
0 · Reply
KevinMarrero147
KevinMarrero147 Sep. 21 at 10:53 AM
$ELVN Biotech with clinical catalyst. High volatility expected. Trading near cash value. Speculative.
0 · Reply
tallguy777
tallguy777 Sep. 16 at 12:02 AM
$ELVN whats concerning me is the short run from 8-8 to 9-3. somethings up? bad earnings?
0 · Reply
bioinv3458
bioinv3458 Sep. 15 at 4:56 PM
$ELVN why down today?
2 · Reply
Richapeslayer_pounce
Richapeslayer_pounce Sep. 8 at 5:36 PM
$ELVN This should be $40 waiting for a break out
1 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 3 at 9:41 AM
$ELVN Brilliant piece that captures ELVN's situation perfectly. So if you want to update your understanding of ELVN or get to know ELVN better, this is essential reading. https://beyondspx.com/quote/ELVN/enliven-therapeutics-prioritizing-precision-in-the-oncology-race-elvn#analysis
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Aug. 28 at 2:57 PM
$ELVN anyone looking for a bump in price for soho conference sept 3?
0 · Reply
Latest News on ELVN
Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update

Nov 12, 2025, 4:05 PM EST - 4 days ago

Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update

Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting

Aug 25, 2025, 6:20 PM EDT - 2 months ago

Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

Aug 13, 2025, 4:05 PM EDT - 3 months ago

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Jun 16, 2025, 4:05 PM EDT - 5 months ago

Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Jun 13, 2025, 9:30 AM EDT - 5 months ago

Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Jun 13, 2025, 6:10 AM EDT - 5 months ago

Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress

Jun 13, 2025, 6:02 AM EDT - 5 months ago

Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress

Enliven Therapeutics to Present at Upcoming Investor Conferences

May 22, 2025, 4:05 PM EDT - 6 months ago

Enliven Therapeutics to Present at Upcoming Investor Conferences

Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

May 14, 2025, 4:05 PM EDT - 6 months ago

Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress

May 14, 2025, 9:56 AM EDT - 6 months ago

Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress

Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting

Apr 2, 2025, 4:03 PM EDT - 8 months ago

Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting

Final Trade: CVX, XLE, ELVN, COF

Mar 21, 2025, 6:38 PM EDT - 8 months ago

Final Trade: CVX, XLE, ELVN, COF

CVX XLE COF

Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Mar 13, 2025, 4:05 PM EDT - 8 months ago

Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Feb 25, 2025, 4:05 PM EST - 9 months ago

Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Biotech walks a 'tightrope' amid unclear funding, regulations

Jan 30, 2025, 7:06 PM EST - 10 months ago

Biotech walks a 'tightrope' amid unclear funding, regulations

DCTH IBB

Enliven's Early Data Stands Out From Peers

Jan 7, 2025, 12:28 AM EST - 11 months ago

Enliven's Early Data Stands Out From Peers

Enliven Therapeutics to Present at the Jefferies London Healthcare Conference

Nov 7, 2024, 4:05 PM EST - 1 year ago

Enliven Therapeutics to Present at the Jefferies London Healthcare Conference

Why Enliven is this analyst's top biotech stock pick

Oct 18, 2024, 7:18 PM EDT - 1 year ago

Why Enliven is this analyst's top biotech stock pick

Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

Sep 28, 2024, 9:35 AM EDT - 1 year ago

Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML

Sep 18, 2024, 4:05 PM EDT - 1 year ago

Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML

Enliven Therapeutics to Present at Two Upcoming Investor Conferences

May 29, 2024, 4:05 PM EDT - 1 year ago

Enliven Therapeutics to Present at Two Upcoming Investor Conferences

Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

Apr 11, 2024, 7:55 AM EDT - 1 year ago

Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors

Apr 9, 2024, 4:05 PM EDT - 1 year ago

Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors

Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024

Mar 28, 2024, 4:05 PM EDT - 1 year ago

Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024

Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates

Mar 19, 2024, 8:30 AM EDT - 1 year ago

Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates

Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

Mar 14, 2024, 4:05 PM EDT - 1 year ago

Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

Enliven Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference

Feb 27, 2024, 4:05 PM EST - 1 year ago

Enliven Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference

Enliven Therapeutics: Preclinical Company With Interesting Value Proposition

Aug 18, 2023, 12:57 PM EDT - 2 years ago

Enliven Therapeutics: Preclinical Company With Interesting Value Proposition

Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

Aug 10, 2023, 4:05 PM EDT - 2 years ago

Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

Enliven Therapeutics Closes Merger with Imara and Private Placement of $165 Million

Feb 23, 2023, 5:20 PM EST - 2 years ago

Enliven Therapeutics Closes Merger with Imara and Private Placement of $165 Million

Imara Announces Stockholder Approval of Merger With Enliven

Feb 22, 2023, 4:01 PM EST - 2 years ago

Imara Announces Stockholder Approval of Merger With Enliven

IMARA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Imara Inc. - IMRA

Jan 25, 2023, 1:07 PM EST - 3 years ago

IMARA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Imara Inc. - IMRA

Enliven Therapeutics and Imara Announce Merger Agreement

Oct 13, 2022, 4:35 PM EDT - 3 years ago

Enliven Therapeutics and Imara Announce Merger Agreement

Imara: Potential Liquidation

Sep 29, 2022, 3:06 PM EDT - 3 years ago

Imara: Potential Liquidation

Read Why Imara Shares Are Falling Today

Apr 5, 2022, 10:13 AM EDT - 3 years ago

Read Why Imara Shares Are Falling Today

Imara Announces Results of Interim Analyses of Tovinontrine (IMR-687) Phase 2b Clinical Trials in Sickle Cell Disease and Beta-Thalassemia

Apr 5, 2022, 6:45 AM EDT - 3 years ago

Imara Announces Results of Interim Analyses of Tovinontrine (IMR-687) Phase 2b Clinical Trials in Sickle Cell Disease and Beta-Thalassemia

Imara (IMRA) CEO, Rahul Ballal on Q4 2021 Results - Earnings Call Transcript

Mar 15, 2022, 11:06 AM EDT - 3 years ago

Imara (IMRA) CEO, Rahul Ballal on Q4 2021 Results - Earnings Call Transcript

Imara to Webcast Conference Call of Full Year 2021 Financial Results and Business Highlights

Mar 8, 2022, 7:00 AM EST - 4 years ago

Imara to Webcast Conference Call of Full Year 2021 Financial Results and Business Highlights

Imara to Present at 11th Annual SVB Leerink Global Healthcare Conference

Feb 10, 2022, 7:00 AM EST - 4 years ago

Imara to Present at 11th Annual SVB Leerink Global Healthcare Conference

Imara To Start Testing Tovinontrine In Heart Failure Patients

Jan 25, 2022, 11:03 AM EST - 4 years ago

Imara To Start Testing Tovinontrine In Heart Failure Patients

Imara Announces FDA Clearance of Investigational New Drug Application (IND) for Tovinontrine (IMR-687) for Heart Failure with Preserved Ejection Fraction (HFpEF)

Jan 25, 2022, 7:00 AM EST - 4 years ago

Imara Announces FDA Clearance of Investigational New Drug Application (IND) for Tovinontrine (IMR-687) for Heart Failure with Preserved Ejection Fraction (HFpEF)

Imara to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference

Jan 5, 2022, 7:00 AM EST - 4 years ago

Imara to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference

Imara Presents Preclinical Data on IMR-261 at the American Society of Hematology (ASH) Annual Meeting 2021

Dec 14, 2021, 7:00 AM EST - 4 years ago

Imara Presents Preclinical Data on IMR-261 at the American Society of Hematology (ASH) Annual Meeting 2021

Imara Changes Primary Endpoint In Mid-Stage Sickle Cell Disease Trial

Nov 22, 2021, 10:36 AM EST - 4 years ago

Imara Changes Primary Endpoint In Mid-Stage Sickle Cell Disease Trial

Imara Announces Primary Endpoint Change in the Ardent Phase 2b Clinical Trial of Tovinontrine (IMR-687) in Sickle Cell Disease

Nov 22, 2021, 7:00 AM EST - 4 years ago

Imara Announces Primary Endpoint Change in the Ardent Phase 2b Clinical Trial of Tovinontrine (IMR-687) in Sickle Cell Disease

Imara's Thalassemia Candidate Shows Reduced Transfusion Burden At Higher Dose

Nov 16, 2021, 11:34 AM EST - 4 years ago

Imara's Thalassemia Candidate Shows Reduced Transfusion Burden At Higher Dose

Imara Announces Interim Analysis Data from Forte Phase 2b Clinical Trial of Tovinontrine (IMR-687) in Transfusion-Dependent Subjects with Beta-thalassemia

Nov 16, 2021, 7:00 AM EST - 4 years ago

Imara Announces Interim Analysis Data from Forte Phase 2b Clinical Trial of Tovinontrine (IMR-687) in Transfusion-Dependent Subjects with Beta-thalassemia

IMARA Inc. (IMRA) CEO Rahul Ballal on Q3 2021 Results - Earnings Call Transcript

Nov 9, 2021, 4:48 PM EST - 4 years ago

IMARA Inc. (IMRA) CEO Rahul Ballal on Q3 2021 Results - Earnings Call Transcript

d_risk
d_risk Nov. 12 at 10:23 PM
$ELVN - Enliven Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors ELVN flags new risks from costly companion diagnostic regulations, urgent need for substantial funding, dependence on key personnel and third parties, cybersecurity threats, and disaster impacts, while expanding on volatility, dilution, regulatory, and commercialization challenges. #Biotechnology #MarketVolatility #CybersecurityThreats #FundingChallenges #RegulatoryRisk 🟢 Added 🟠 Removed https://d-risk.ai/ELVN/10-Q/2025-11-12
0 · Reply
notreload_ai
notreload_ai Nov. 3 at 8:30 PM
Mizuho says $TERN TERN-701 data looks fine, but the market is overreacting by pushing $ELVN stock down 19%. The two treat different patients [ELVN-001], so the drop “makes no sense.” Mizuho expects Enliven to rebound on strong fundamentals; keeps $41 target and Outperform.
0 · Reply
Quantumup
Quantumup Nov. 3 at 7:36 PM
Oppenheimer⬆️ $TERN's PT to $24 from $17 and reiterated at an Outperform rating. $NVS Oppenheimer said, TERN shares are rallying (+88% vs. -3% $XBI and -20% $ELVN) following a newly-released ASH abstract detailing promising preliminary Ph1 CARDINAL data with June 2025 data cutoff, specifically: 1) impressive cumulative 6-mo. MMR rate of 75% (n=24/32), which appears potentially superior against asciminib [NVS] and ELVN-001; 2) 64% of evaluable patients (n=14/22) not in MMR at baseline achieved MMR, also notable compared to the 6-mo. MMR achievement for asciminib/ELVN-001; 3) 6-mo. overall MMR in asciminib-experienced patients of 60% versus 32% in ELVN-001's Ph1 ENABLE trial; and 4) on safety, no dose-limiting toxicities or pancreatic/cardiovascular safety signals, with only one patient discontinuing the study due to adverse events. We see these initial results bolstering '701's competitive positioning and accordingly raise our PT to $24 (vs. $17 prior).
0 · Reply
kshonstocks
kshonstocks Sep. 29 at 2:29 PM
$ELVN positive Barrons
0 · Reply
KevinMarrero147
KevinMarrero147 Sep. 21 at 10:53 AM
$ELVN Biotech with clinical catalyst. High volatility expected. Trading near cash value. Speculative.
0 · Reply
tallguy777
tallguy777 Sep. 16 at 12:02 AM
$ELVN whats concerning me is the short run from 8-8 to 9-3. somethings up? bad earnings?
0 · Reply
bioinv3458
bioinv3458 Sep. 15 at 4:56 PM
$ELVN why down today?
2 · Reply
Richapeslayer_pounce
Richapeslayer_pounce Sep. 8 at 5:36 PM
$ELVN This should be $40 waiting for a break out
1 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 3 at 9:41 AM
$ELVN Brilliant piece that captures ELVN's situation perfectly. So if you want to update your understanding of ELVN or get to know ELVN better, this is essential reading. https://beyondspx.com/quote/ELVN/enliven-therapeutics-prioritizing-precision-in-the-oncology-race-elvn#analysis
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Aug. 28 at 2:57 PM
$ELVN anyone looking for a bump in price for soho conference sept 3?
0 · Reply
EvBullforever13
EvBullforever13 Aug. 24 at 8:04 PM
$OSCR $UNH $MOH $ELVN
0 · Reply
MarketProfileSecurities
MarketProfileSecurities Aug. 23 at 1:23 PM
$ELVN Enliven Therapeutics Inc is a clinical stage oncology company with targeted therapy platform
0 · Reply
IN0V8
IN0V8 Jul. 2 at 1:53 PM
$ELVN Watch / Opportunity H.C. Wainwright raises target price to $48 from $40
1 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Jul. 2 at 11:03 AM
WATCHLIST JUL 02 2025 $GRYP American Bitcoin Expected To Trade On Nasdaq Under Ticker Symbol "ABTC" Following Stock-For-Stock Merger With Gryphon Digital Mining $TTD Citigroup Maintains Buy on Trade Desk, Raises Price Target to $90 $HUT Hut 8's Four Natural Gas-Fired Power Plants In Ontario Bags 5-Yr Capacity Contract With Ontario Independent Electricity System Operator $VIAV VIAVI Adds Colocation to Arizona Open RAN Lab, Boosting Secure Testing for US Telecom Innovation $ELVN HC Wainwright & Co. Maintains Buy on Enliven Therapeutics, Raises Price Target to $48
0 · Reply
JarvisFlow
JarvisFlow Jul. 2 at 11:00 AM
HC Wainwright & Co. has updated their rating for Enliven Therapeutics ( $ELVN ) to Buy with a price target of 48.
0 · Reply
TopLight2025
TopLight2025 Jun. 23 at 3:28 PM
$ELVN
0 · Reply
StocktwitsNews
StocktwitsNews Jun. 23 at 4:50 AM
Enliven Short Interest Falls To 14-Month Low After Leukemia Trial Data, Goldman Initiates With ‘Buy’ $ELVN https://stocktwits.com/news/equity/markets/enliven-short-interest-falls-to-14-month-low-after-leukemia-trial-data-goldman-initiates-with-buy/chmPAwdRR59
1 · Reply
Quantumup
Quantumup Jun. 20 at 7:40 PM
Goldman Sachs, on 6/16,🏁 $ELVN Buy-$37. $TERN $AAPG $TAK INCY $NVS PFE BMY AZN #EHA2025 Goldman Sachs said in its initiation report: "Given continued positive Ph1 data and the announcement of a planned Ph3 initiation in 2026 for tyrosine kinase inhibitor (TKI) ELVN-001 in chronic myeloid leukemia (CML), we assign a Buy rating to $ELVN with a $37, 12-month price target, from the previous Early-Stage Biotech designation." Goldman Sachs went on to say:
1 · Reply
TopLight2025
TopLight2025 Jun. 20 at 6:11 PM
$ELVN
0 · Reply
Quantumup
Quantumup Jun. 20 at 5:50 PM
TD Cowen Named Buy Rated $ELVN as a Best Smidcap Idea and said "Strong Data Position '001 To Advance Care In $B+ CML Market" $TERN $AAPG $TAK $NVS PFE AZN BMY #EHA2025 TD Cowen additionally said, "ELVN-001 is designed to improve upon prior TKIs for CML. At EHA ELVN-001 produced strong proof-of-concept data with a high MMR rate and benign safety profile, positioning it to become a standard therapy in this multi-$B market. ELVN-001 will enter pivotal development in 2026 and we project peak sales of $3B. We think $ELVN is undervalued for '001's potential. It is a top smidcap biotech pick."
1 · Reply
TopLight2025
TopLight2025 Jun. 16 at 9:49 PM
$ELVN https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250616:nPn7yLpzPa&default-theme=true
0 · Reply
JarvisFlow
JarvisFlow Jun. 16 at 1:38 PM
Goldman Sachs updates rating for Enliven Therapeutics ( $ELVN ) to Buy, target set at 37.
0 · Reply